Tesamorelin legal status: FDA-approved use vs off-label reality

Last updated 2026-07-25

Is tesamorelin FDA-approved?

Yes, but for one specific thing. Tesamorelin is FDA-approved under the brand name Egrifta (and later Egrifta SV) as a growth-hormone-releasing hormone (GHRH) analogue for reducing excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[1][2]. That approval came out of two pooled phase 3, multicenter, double-blind, placebo-controlled trials, plus a safety extension, published in the Journal of Clinical Endocrinology and Metabolism ^[3]. That's the entire label. The FDA did not approve tesamorelin for weight loss in people without HIV, for muscle gain, for anti-aging, or for general "GH support." If you see it marketed for any of those uses, that's off-label promotion, not an FDA-sanctioned indication. You can verify any drug's approval status and labeled indications directly through Drugs@FDA, the FDA's own database of approved drug products ^[4]. That's the fastest way to confirm what a drug is actually cleared for, rather than trusting a seller's marketing copy.

What exactly does the approved indication cover?

The approved indication is narrow: adults with HIV who have lipodystrophy, specifically excess visceral fat around the organs in the abdomen. Lipodystrophy itself is a recognized clinical syndrome with its own diagnostic criteria, described in detail in endocrinology literature on how to identify fat redistribution disorders and in a broader clinical approach to lipodystrophy patients published in the Journal of Clinical Endocrinology and Metabolism ^[5]. In the key trials behind the approval, tesamorelin reduced visceral adipose tissue and improved some metabolic and liver markers in this population, with effects on liver enzymes tied specifically to the degree of visceral fat reduction ^[6]. A 2019 randomized, double-blind, multicenter trial also found tesamorelin reduced liver fat content in HIV patients with non-alcoholic fatty liver disease (NAFLD), an effect the study's authors describe directly . More recent work looked at tesamorelin in people with HIV managed on integrase inhibitor-based regimens, a more current standard of HIV care than the older trials used ^[7]. None of that generalizes to fat loss in people without HIV. It's HIV-specific lipodystrophy data, full stop.

What does 'off-label' actually mean for tesamorelin?

Off-label means a licensed prescriber gives an FDA-approved drug for a use, dose, or population the FDA didn't review and clear. It's legal for physicians to prescribe off-label in the United States. It is not legal for a manufacturer or seller to market a drug for an unapproved use, and the FDA's own regulation on "intended use" spells out how the agency determines what a product is being marketed for, based on labeling, advertising, and how it's promoted [/current/title-21/chapter-I/subchapter-C/part-201/subpart-H/section-201.128] ^[8]. So if you're offered tesamorelin for general anti-aging or fat loss with no HIV-related diagnosis, the prescribing itself may be within a doctor's legal discretion, but any marketing claiming it's approved or proven for that use is not accurate. The evidence base plainly doesn't support that. There's no phase 3 trial in the general population; the entire approval rests on HIV-associated lipodystrophy data ^[3][9]. A 2011 review in Drugs walked through the clinical trial evidence supporting the HIV-lipodystrophy label specifically ^[8], and a companion review in The Annals of Pharmacotherapy covers the same ground with a pharmacist's lens on dosing and monitoring ^[9]. Neither extends the claims beyond that population.

Can you legally get compounded tesamorelin instead of the branded drug?

This is where it gets genuinely complicated, and where most of the confusion in the market comes from. Compounded tesamorelin is not the same legal category as FDA-approved Egrifta. Compounding pharmacies operate under a separate framework: 503A pharmacies (traditional compounding for a specific patient) and 503B outsourcing facilities (larger-scale compounding, often for offices or clinics) ^[10][11]. The key legal hook is the FDA's Bulks List. Under 21 CFR 216.23, the FDA maintains a list of bulk drug substances that 503A pharmacies may use in compounding ^[10]. A separate list, 21 CFR 216.24, covers what 503B outsourcing facilities may use ^[11]. Whether tesamorelin, or any peptide, appears on these lists (and in what form) changes over time as the FDA updates its nominated substances list ^[12]. The underlying statute governing pharmacy compounding is 21 U.S.C. § 353a ^[7], which sets conditions like a valid prescription and no copying of a commercially available FDA-approved drug in essentially the same form. That last point matters a lot for tesamorelin specifically. Because Egrifta is an FDA-approved, commercially available drug, compounding a copy of it runs into the restriction against compounding "essentially a copy" of an approved drug. Compounders and clinics navigate this in different ways, and enforcement has varied. If you're offered a compounded tesamorelin product, ask directly which pharmacy is producing it, whether it's 503A or 503B, and what's actually in the vial. If nobody can answer clearly, that's a red flag, not a technicality.

Is buying tesamorelin online without a prescription legal?

No, not for legitimate medical use. Tesamorelin, whether branded Egrifta or compounded, requires a prescription. "Research chemical" or "not for human consumption" sellers exist specifically to dodge that requirement, and the products they ship have no chain of custody, no verified purity, and no FDA or state pharmacy board oversight. A 2021 paper in Drug Testing and Analysis on detecting GHRH synthetic analogs notes these compounds circulate partly because they're used off-label and sometimes sourced outside regulated channels, which is exactly why anti-doping labs developed detection methods for them ^[12]. That paper exists because misuse is common enough to need a testing protocol, which tells you something about the gray market's size. If you want tesamorelin, the legitimate path is a prescription from a licensed provider, filled through a pharmacy operating under either the standard FDA-approved supply chain or a compliant 503A/503B compounding arrangement. If you're weighing tesamorelin cost across sourcing options, price alone is a poor signal of legitimacy. Cheap, no-prescription vials are the products most likely to be mislabeled or underdosed.

Does tesamorelin's legal status differ for athletes or bodybuilders?

Yes, in an important way that has nothing to do with the FDA. Tesamorelin and other GHRH analogues are banned substances under most competitive sports anti-doping codes, because they stimulate endogenous growth hormone release. The 2021 Drug Testing and Analysis paper on detecting GHRH synthetic analogs describes the analytical methods anti-doping labs use to catch these compounds in athlete samples ^[12], which is a strong indicator that regulators treat tesamorelin as a doping risk regardless of its HIV-lipodystrophy approval. Recent sports medicine literature has taken this seriously enough to publish primers for physicians on injectable peptide therapies in this context, covering both approved and unapproved products athletes use ^[2], along with a broader review of safety and efficacy data for peptide therapies used off-label for musculoskeletal injury and athletic performance ^[11]. Orthopaedic literature is now doing the same, cataloguing peptides used in sports medicine settings and the evidence gaps around them ^[1]. Bottom line for athletes: legal to obtain with a valid prescription for an approved indication, but very likely to violate competition anti-doping rules regardless of how you obtained it. That's a separate question from FDA legality, and it trips people up.

What's the actual clinical evidence behind the approval?

Solid, for the specific population studied. The approval rests on pooled phase 3 data from two multicenter, randomized, double-blind, placebo-controlled trials with a safety extension phase, published in 2010 ^[3]. That's real controlled-trial evidence, not a small open-label pilot. Follow-up work has kept building on it. A meta-analysis of randomized controlled trials looked at tesamorelin's effects on body composition, hepatic fat, and metabolic and safety outcomes specifically in HIV-associated lipodystrophy ^[13]. Separate trials examined visceral fat reduction tied to liver enzyme improvement ^[6], hepatic fat and NAFLD outcomes , fat quality changes independent of fat quantity ^[14], inflammatory markers linked to visceral fat reduction , and even neurocognitive outcomes in people with HIV and abdominal obesity ^[15]. A post hoc analysis also looked specifically at patients with and without dorsocervical fat pads (sometimes called "buffalo hump") within the original phase 3 dataset . That's a genuinely deep evidence base for the approved indication. It just doesn't stretch to cover "general visceral fat in people without HIV" or "anti-aging GH support," claims you'll see attached to tesamorelin in off-label marketing. Population pharmacokinetics have also been modeled in both HIV-infected patients and healthy subjects ^[16], which is useful dosing science but again isn't the same as an efficacy claim outside the approved population.

How does tesamorelin's legal status compare to other GH-related peptides?

Tesamorelin stands apart from most peptides discussed in the anti-aging and performance space because it actually has an FDA approval and a real NDA-backed label. Most other GHRH analogues, GHRPs, and related peptides people ask about (sermorelin, ipamorelin, CJC-1295, and others) do not have that status; they exist purely in the compounding and research-use space, without phase 3 trial data behind a specific approved indication. | Status | Tesamorelin (Egrifta) | Most other GH-secretagogue peptides |

What should you check before starting tesamorelin, legally speaking?

A few concrete things. First, ask whether you're being prescribed branded Egrifta/Egrifta SV or a compounded version, and if compounded, which pharmacy and under which framework (503A or 503B) ^[10][11]. Second, ask what diagnosis is supporting the prescription; if it's HIV-associated lipodystrophy, you're squarely on-label. If it's anything else, you're in off-label territory, which can still be a legitimate medical decision, but you deserve to know that plainly. Third, understand the dosing and administration basics before you commit, covered in more detail in our guides on how to reconstitute tesamorelin, tesamorelin injection sites, and tesamorelin how to inject. Fourth, if you're planning a defined course rather than indefinite use, our piece on tesamorelin cycle length and best time to take tesamorelin peptide covers the practical scheduling questions that come up once the legal basics are settled. Tesamorelin Co works from a provider-reviewed model precisely because the legal and clinical picture here has real nuance: an approved drug, a narrow label, and a much wider off-label reality. If you're evaluating sourcing options, that provider-reviewed route paired with a legitimate fulfilling pharmacy is the way to keep the legal and quality questions answered up front, rather than discovered after the fact.

What happens if tesamorelin is prescribed for something outside the approved use?

Nothing automatically illegal happens to you as a patient. Off-label prescribing is a normal, legal part of medical practice in the United States, and physicians retain discretion to prescribe FDA-approved drugs for unapproved uses when they judge it appropriate. What changes is the evidence backing the decision, not its legality. The risk sits more with marketing and sourcing than with the prescription itself. A clinic that implies tesamorelin is "FDA-approved for fat loss" broadly, without the HIV-lipodystrophy qualifier, is misrepresenting the label. A seller offering tesamorelin without any prescription requirement is operating outside the pharmacy framework altogether, regardless of what indication it's for. So the practical takeaway: off-label use itself isn't a legal problem. Vague marketing that erases the narrow indication, and no-prescription sourcing that skips medical oversight entirely, are the two things to watch for.

Frequently asked questions

Is tesamorelin FDA approved for weight loss?

No. Tesamorelin (Egrifta) is FDA-approved only to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy ^[1][2]. It is not approved for general weight loss, obesity, or fat loss in people without HIV. Any use for those purposes is off-label, meaning it's prescribed at a doctor's discretion without FDA review of that specific use.

Is compounded tesamorelin legal?

It depends on the pharmacy and the substance's current status on the FDA's Bulks Lists under 21 CFR 216.23 (503A) and 216.24 (503B) ^[4][5], plus compliance with 21 U.S.C. § 353a's compounding conditions ^[6]. Because tesamorelin is a commercially available approved drug, compounding a copy of it raises extra legal scrutiny; ask your pharmacy directly about its compliance basis.

Can a doctor legally prescribe tesamorelin off-label?

Yes. Off-label prescribing of FDA-approved drugs is legal and common in U.S. medicine. A licensed physician can prescribe tesamorelin for a use outside the HIV-lipodystrophy label based on clinical judgment. What's not legal is a manufacturer or seller marketing the drug for unapproved uses, per FDA rules on intended use ^[10].

Do you need a prescription for tesamorelin?

Yes. Tesamorelin, whether the branded product Egrifta or a compounded version, requires a valid prescription from a licensed provider. Products sold online as "research chemicals" without a prescription requirement fall outside the regulated pharmacy supply chain and carry no verified purity or dosing accuracy.

Is tesamorelin banned in professional sports?

Effectively yes. Tesamorelin stimulates endogenous growth hormone release, which places it in the category of substances anti-doping labs test for; detection methods for GHRH analogues like tesamorelin are described in a 2021 Drug Testing and Analysis paper ^[8]. Athletes under competition anti-doping codes should assume tesamorelin use is prohibited regardless of how it was obtained.

What is the FDA-approved brand name for tesamorelin?

Egrifta, later reformulated as Egrifta SV. Both are FDA-approved GHRH analogues indicated for reducing excess visceral adipose tissue in HIV patients with lipodystrophy ^[1][2]. You can confirm current approval status and labeling directly through the FDA's Drugs@FDA database ^[7].

What was the evidence that got tesamorelin approved?

Two pooled multicenter, randomized, double-blind, placebo-controlled phase 3 trials with a safety extension phase, in HIV-infected patients with excess abdominal fat, published in the Journal of Clinical Endocrinology and Metabolism in 2010 ^[3]. Numerous follow-up studies on liver fat, inflammatory markers, and fat quality have built on that core dataset ^{[16][17][20][21]}.

Is it legal to buy tesamorelin without a diagnosis of HIV lipodystrophy?

The legal question and the labeled-use question are different. A provider can legally prescribe it off-label without an HIV lipodystrophy diagnosis, at their discretion. But no seller can legally claim it's FDA-approved for that other use. If a diagnosis isn't required at all and no prescription is checked, that's outside the legal pharmacy system entirely.

What's the difference between 503A and 503B compounding for tesamorelin?

503A covers traditional compounding pharmacies making patient-specific preparations under 21 CFR 216.23, generally smaller scale ^[4]. 503B covers outsourcing facilities that can compound in larger batches, often for clinics, under 21 CFR 216.24, with somewhat different oversight ^[5]. Both operate under the statutory framework in 21 U.S.C. § 353a ^[6].

Does having FDA approval mean tesamorelin is proven for anti-aging use?

No. FDA approval covers a specific indication, HIV-associated lipodystrophy visceral fat reduction ^[1][2]. It does not certify the drug for anti-aging, general muscle gain, or GH optimization in healthy adults without HIV. Marketing that implies broader proven benefit from the approval status is misrepresenting what the FDA actually reviewed.

Can tesamorelin show up on a drug test?

For standard workplace drug screens, no; those don't test for GHRH analogues. For sports anti-doping testing, yes, specific analytical methods have been developed to detect GHRH synthetic analogues like tesamorelin in athlete samples ^[8], since these compounds are prohibited under most competitive sport doping codes.

Who actually qualifies for the FDA-approved tesamorelin indication?

Adults with HIV infection who have lipodystrophy with excess visceral abdominal fat, as defined in the phase 3 trials supporting approval ^[3]. Diagnosis of lipodystrophy syndromes follows criteria described in clinical endocrinology literature on identifying fat redistribution disorders ^[14][24]. Outside that population and that specific fat distribution problem, use is off-label.

Sources

1. PubMed, Tesamorelin (2012): Tesamorelin is FDA-approved as a GHRH analogue for reducing excess visceral adipose tissue in HIV-associated lipodystrophy.
2. PubMed, Tesamorelin, Nature Reviews Drug Discovery (2011): Tesamorelin (Egrifta) received FDA approval for the HIV lipodystrophy visceral fat indication.
3. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat, J Clin Endocrinol Metab (2010): Pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data supported the approval.
4. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the FDA bulk drug substances list that traditional 503A compounding pharmacies may use.
5. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the FDA bulk drug substances list that 503B outsourcing facilities may use.
6. Cornell Law School, 21 U.S.C. § 353a: Sets statutory conditions for pharmacy compounding, including valid prescription requirements and restrictions on copying approved drugs.
7. FDA, Drugs@FDA database: Allows verification of a drug's current FDA approval status and approved labeling.
8. PubMed, Advances in the detection of growth hormone releasing hormone synthetic analogs, Drug Testing and Analysis (2021): Anti-doping laboratories have developed detection methods for GHRH synthetic analogues like tesamorelin because of their use outside approved medical contexts and prohibition in sport.
9. PubMed, Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity, J Infect Dis (2025): Studied tesamorelin's effect on neurocognitive outcomes specifically in HIV patients with abdominal obesity.
10. PubMed, Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy, Drugs (2011): Reviews the clinical trial evidence supporting tesamorelin's approved use in HIV-associated lipodystrophy.
11. PubMed, Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy, Ann Pharmacother (2012): Reviews dosing and monitoring considerations for tesamorelin specific to the approved HIV lipodystrophy indication.
12. PubMed, Approach to the Patient With Lipodystrophy, J Clin Endocrinol Metab (2022): Describes clinical criteria for diagnosing lipodystrophy syndromes relevant to the approved patient population.
13. PubMed, Tesamorelin improves fat quality independent of changes in fat quantity, AIDS (2021): Found tesamorelin affects fat quality in HIV patients independent of changes in overall fat quantity.
14. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, Obesity Research & Clinical Practice (2026): Meta-analysis of RCTs on tesamorelin's body composition, hepatic fat, metabolic, and safety outcomes in HIV-associated lipodystrophy.
15. PubMed, Population pharmacokinetic analysis of tesamorelin, Clin Pharmacokinet (2015): Modeled tesamorelin pharmacokinetics in both HIV-infected patients and healthy subjects.
16. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV, AIDS (2017): Tied the degree of visceral fat reduction from tesamorelin to improvement in liver enzymes in HIV patients.
17. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV, Lancet HIV (2019): Randomized, double-blind, multicenter trial found tesamorelin reduced liver fat content in HIV patients with NAFLD.
18. PubMed, Effect of tesamorelin in people with HIV with and without dorsocervical fat, J Clin Transl Sci (2023): Post hoc analysis of the phase 3 trial data examined outcomes in patients with and without dorsocervical fat pads.
19. PubMed, How to diagnose a lipodystrophy syndrome, Annales d'Endocrinologie (2012): Describes diagnostic approach to lipodystrophy syndromes, the condition the approved indication targets.
20. PubMed, Effects of tesamorelin on inflammatory markers in HIV patients, AIDS (2011): Studied the relationship between tesamorelin-induced visceral fat reduction and inflammatory marker changes.